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Abstract
Background: Proteins overexpressed on the surface of tumor cells can be selectively targeted.
Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2)
are among the most often targeted proteins. The level and stability of expression in both primary
tumors and corresponding metastases is crucial in the assessment of a receptor as target for
imaging in nuclear medicine and for various forms of therapy. So far, the expression of EGFR and
HER2 has only been determined in primary cervical cancers, and we have not found published data
regarding the receptor status in corresponding metastatic lesions. The goal of this study was to
evaluate whether any of these receptors are suitable as target for clinical diagnosis and therapy.
Methods: Expression of EGFR and HER2 was investigated immunohistochemically in both lymph
node metastases and corresponding primary cervical cancers (n = 53). HER2 and EGFR expression
was scored using HercepTest criteria (0, 1+, 2+ or 3+).
Results: EGFR overexpression (2+ or 3+) was found in 64% (35/53) of the primary cervical tumors
and 60% (32/53) of the corresponding lymph node metastases. There was a good concordance
between the primary tumors and the paired metastases regarding EGFR expression. Only four
patients who had 2+ or 3+ in the primary tumors changed to 0 or 1+ in lymph node metastases,
and another two cases changed the other way around. None of the primary tumors or the lymph
node metastases expressed HER2 protein.
Conclusion:  The EGFR expression seems to be common and stable during cervical cancer
metastasis, which is encouraging for testing of EGFR targeted radiotherapy. HER2 appears to be of
poor interest as a potential target in the treatment of cervical cancer.
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Background
Cervical cancer represents the second most frequent
malignancy in women worldwide, particularly in devel-
oping countries [1]. While curable in early stages, the
prognosis for advanced stage disease is poor [2]. Radia-
tion has been the gold standard of therapy for many dec-
ades. Nowadays, concurrent cisplatin-based
chemoradiotherapy has been considered as the standard
therapeutic modality for locally advanced cervical cancer
[3-6]. However, such treatment remains suboptimal with
histopathological residual tumor observed in 40–50% of
patients [7,8]. Those presenting with recurrent or meta-
static disease have limited treatment options [2,9], and
the 5-year survival is less than 5% [10]. There is a clear
need for novel, more effective therapeutical strategies to
improve overall survival and the quality of life for
advanced, recurrent and disseminated cervical cancer.
Thus, the testing of molecular targeted therapies against
cervical cancer is a logical step to follow [11]. Another
strategy is receptor-mediated tumor targeted radiotherapy
[12], which is based on the delivery of therapeutically rel-
evant radionuclides directly to disseminated tumor cells,
with hopefully minimal damage to normal tissues.
Proteins overexpressed on the surface of tumor cells can
be selectively targeted. Epidermal growth factor receptor
(EGFR) and human epidermal growth factor receptor 2
(HER2) are among the most often targeted proteins. The
presence of EGFR and HER2 receptors have been associ-
ated with accelerated tumor progression and therapeutic
resistance for several types of malignancies, including cer-
vical cancer. The causal relationship of EGFR and HER2
receptor network to disease progression and resistance to
therapy provides a rationale for therapeutic intervention.
Nowadays, EGFR targeted drugs, both chimeric mono-
clonal antibody Cetuximab (Erbitux) and the small-mol-
ecule tyrosine kinase inhibitors (e.g. Iressa and Tarceva)
[13-15], have been approved by FDA. Clinical trials of
Cetuximab, either alone or in combination with radio-
therapy/chemotherapy, have recently demonstrated effi-
cacy in patients with head and neck cancer, colorectal
cancer and lung cancer [16-18]. The humanized mono-
clonal antibody trastuzumab (Herceptin), which is the
first clinically available oncogene-targeted therapeutic
agent for treatment of solid tumors, has boosted the inter-
est of physicians in targeting therapy, as therapeutic bene-
fit was proved in patients with HER2-positive metastatic
breast cancer [19]. On the basis of the preliminary success,
clinical trials are currently investigating the therapeutic
potential of molecular targeted drugs in other human
malignancies including cervical cancer [20].
In a recent phase II trial reported by Goncalves et al,
patients with recurring locoregionally advanced or meta-
static cervical cancer were treated with gefitinib 500 mg/
day, EGFR expression levels by means of immunohisto-
chemistry did not correlate with tumor response and dis-
ease control [20]. This is not unexpected, since EGFR
expression does not necessarily correlate with EGFR recep-
tor activation. Other molecular alterations, such as EGFR
gene amplification, mutations of the tyrosine kinase
domain, and EGFR phosphorylation status, might be use-
ful indicators for the response to EGFR signaling inhibi-
tion. However, in the case of targeted radionuclide
therapy, tumor cells are mainly killed with delivered radi-
ation and therapeutic efficiency is only dependent on the
receptor expression and not whether the receptor function
can be blocked or not. Thus, receptor overexpression is
considered necessary for the success of targeted radiother-
apy.
Previous studies have shown EGFR to be frequently
expressed in primary cervical cancer [21-25], and that
EGFR expression is correlated with poor prognosis [25-
27]. Positive staining of HER2 in cervical cancer has been
reported to vary wildly in the earlier studies [28-30]. How-
ever, according to the recent reports using HercepTest
grading system, HER2 overexpression was considered to
be a rare event in primary cervical cancer [31,32].
The literature was reviewed for similar investigations, but
no other studies comparing primary cervical cancers and
their corresponding metastases regarding EGFR and HER2
were found by the authors. It is still unclear whether the
metastases lose, gain, or retain the receptor status relative
to the primary tumors. For a receptor to be of interest for
targeting, similar expression in both the primary tumors
and the disseminated lesions are required. Investigation
into the receptor status between metastases and the pri-
mary tumors will provide valuable information on
whether these receptors are suitable as target for diagnos-
tic and/or therapeutic procedures. In the present study,
the expression of EGFR and HER2 was investigated immu-
nohistochemically in a series of 53 primary cervical can-
cers and corresponding lymph node metastases.
Methods
Patients and Samples
Patients with cervical cancer who were treated with radical
hysterectomy and systematic pelvic lymphadenectomy
between 2002 and 2003, were enrolled in the present
study. Tumor samples from all patients were obtained at
the time of operation through the Gynecologic Oncology
Department and the Pathology Department, Zhejiang
Cancer Hospital, under ethical approval of the Institu-
tional Review Board of Zhejiang Cancer Hospital.
Informed consent for scientific evaluation had been
obtained from patients. Paraffin sections from both the
primary tumors and the corresponding lymph nodeBMC Cancer 2008, 8:232 http://www.biomedcentral.com/1471-2407/8/232
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metastases were required for inclusion. Tissue samples
were not taken from distant metastases so these were not
available for analysis. Totally, 53 patients with high qual-
ity material were finally included in the study. Clinical
information was obtained from the hospital records and
included patient age, disease stage, histological pattern,
differentiation, tumor size, nodal involvement, lym-
phatic/vascular invasion, vaginal invasion, parametrial
invasion, ovarian metastasis. All patients had a pathologic
diagnosis of squamous cell carcinoma. Ovarian metastasis
was not found in this set of cases. The patient and tumor
characteristics of the analyzed cases are shown in Table 1.
Briefly, the tissues were fixed in 4% buffered formalin,
processed and embedded in paraffin. Sections, 4-μm
thick, were then cut and deparaffinized in xylene and
hydrated through graded concentrations of ethanol to dis-
tilled water.
EGFR-staining
EGFR was assessed by immunohistochemistry using a
streptavidin-biotin complex technique as previously
described [33]. After deparaffinization of the sections,
endogenous peroxidase was blocked in 0.3% H2O2 in PBS
for 20 min. For antigen retrieval, the sections were submit-
ted to high temperature and pressure with Tris-EDTA
buffer (pH 9) for 5 min. The slides were preincubated in
PBS for 10 min. The primary mouse monoclonal antibody
directed against EGF receptor (clone 31G7, Zymed labs,
South San Francisco, CA, USA) receptor were diluted
1:100, and incubated overnight at 4°C. The secondary
biotinylated antibodies (goat anti-mouse from Dako,
Glostrup, Denmark) and the peroxidase-labelled strepta-
vidin-biotin complex (Dako) were diluted 1:200 and
incubated for 30 min at room temperature. All slides were
developed in 0.05% diamino benzidine (Sigma, St Louis,
MO, USA) for 5 min and counterstained in Harris haema-
toxylin (Sigma). Finally, the slides were dehydrated
through graded alcohol to xylene and mounted in organic
mounting medium.
HER2-staining
The HER2 immunohistochemical staining was made as
previously described [34]. After deparaffinization, the sec-
tions were incubated in methanol and hydrogen peroxide
for 30 min quenching endogenous peroxidase. Antigen
retrieval was done in waterbath at 98°C, pH 6 for 40 min-
utes. Thereafter the slides were cooled at room tempera-
ture and then washed in distilled water.
Immunohistochemical staining was performed using the
Elite ABC Kit (Vectastain, Vector Laboratories, Burlin-
game, CA). Blocking serum was applied for 15 min and
followed by incubation with rabbit anti-human c-erbB-2
oncoprotein (code No. A 0485, Dako) diluted 1:350. Sec-
tions were then incubated with the biotinylated secondary
antibody and were visualised by using the peroxidase sub-
strate 3-amino-9-ethyl-carbazole (AEC) (Sigma A-5754)
as chromogen. Finally, the sections were counterstained
with Mayer's haematoxylin and mounted.
EGFR and HER2-scores
The HER2 expression was scored using the HercepTest
scoring criterion. The HER2-score was based on a scale
where 0 corresponded to tumor cells that were completely
negative, 1+ corresponded to faint perceptible staining of
the tumor cell membranes, 2+ corresponded to moderate
staining of the entire tumor cell membranes and 3+ was
strong circumferential staining of the entire tumor cell
membranes creating a fishnet pattern. The Canadian and
the DAKO HercepTest guidelines were applied, which
require more than 10% of the tumor cells to be stained
[35]. Cytoplasmic staining was considered non-specific
and was not included in the scoring. As positive controls
we used in house positive control tissue sections as well as
positive control sections supplied by DAKO. As negative
controls we used normal tissues, which are expected not
to express HER2 such as connective tissue seen in the same
sections as the tumor cells. In the metastases sections we
Table 1: Tumor and patient characteristics (n = 53)
Characteristics Patients, n (%)
Differentiation
High 5 (9.4)
Moderate 42 (79.3)
Low 6 (11.3)
FIGO Stage
IB 16 (30.2)
IIA 35 (66.0)
IIB 1 (1.9)
IIIB 1 (1.9)
Tumor size
> 5 cm 9 (17.0)
3–5 cm 26 (49.0)
< 3 cm 18 (34.0)
Lymphatic or vascular space invasion
Positive 26 (49.1)
Negative 27 (50.9)
Vaginal invasion
Positive 37 (69.8)
Negative 16 (30.2)
Parametrial invasion
Positive 6 (11.3)
Negative 47 (88.7)
Age (years)
Medium 48
Range 29–72BMC Cancer 2008, 8:232 http://www.biomedcentral.com/1471-2407/8/232
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used lymphocytes and the surrounding capsule of the
lymph nodes as negative internal controls. The expression
pattern of EGFR is quite similar to that of HER2, and EGFR
expression was therefore evaluated using the same scoring
criterion as for HER2. As EGFR positive controls we used
in house positive control skin tissue sections. As negative
controls we used connective tissue seen in the same sec-
tions as the tumor cells. In the metastases sections we used
lymphocytes and the surrounding capsule of the lymph
nodes as negative internal controls.
Results
Expression of EGFR
Table 2 shows the EGFR-scores for the analyzed 53 pri-
mary cervical squamous cell carcinoma and the corre-
sponding 53 lymph node metastases. EGFR
overexpression (2+ or 3+) was found in 64% (34/53) of
the primary cervical tumors and 60% (32/53) of the cor-
responding lymph node metastases. There was a good
agreement between the primary tumors and the corre-
sponding lymph node metastases in the majority of cases.
Fifteen changes were observed. However, there were only
four patients who had 2+ or 3+ in the primary tumors and
changed to 0 or 1+ in lymph node metastases, and
another two patients who had 0 or 1+ in the primary
tumors and changed to 2+ or 3+ in lymph node metas-
tases. Examples of staining patterns for a primary tumor
and the corresponding metastasis (which both were
scored as 3+) are shown in Figure 1A and 1B.
Expression of HER2
Among the 53 paired samples, none of the primary
tumors or the lymph node metastases expressed HER2
protein. In fact, a few strong membrane stained tumor
cells were seen in 2 cases, but the stained cells were less
than 10% of total tumor cells (Figure 2). So, these two
cases were also interpreted as negative.
Comparisons of immunohistochemical EGFR staining of primary cervical carcinoma (A) and corresponding metastases (B) Figure 1
Comparisons of immunohistochemical EGFR staining of primary cervical carcinoma (A) and corresponding 
metastases (B). Both A and B (from the same patient) were scored 3+. The micrographs were taken with objective × 40.BMC Cancer 2008, 8:232 http://www.biomedcentral.com/1471-2407/8/232
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Discussion
The aim of this study was to evaluate the EGFR and HER2
receptor expression, using immunohistochemical analy-
ses, in primary cervical cancers and determine if the
expression is retained in lymph node metastases. The goal
was to evaluate whether any of these receptors are suitable
as target for radionuclide based imaging and radiation
therapy.
Overexpression of EGFR in cervical cancer has been
reported to be common (ranges from 26–72%) [21-25].
However, it is unclear whether metastases lose, gain, or
retain EGFR status relative to the primary cervical tumors.
Studies on the EGFR status of metastatic lymph node of
cervical cancer will provide precious knowledge to evalu-
ate whether the receptor is of interest for diagnostic and/
or therapeutic procedures or not.
EGFR overexpression (2+/3+) was found in 64% of the
primary lesions. Our result is consistent with the former
findings of high EGFR overexpression in cervical cancer
[23-25]. Furthermore, we found that the frequency of
EGFR overexpression in lymph node metastases was
approximately as high as in the primary lesions of cervical
cancer. Although 15 changes were observed, only 4
patients with EGFR overexpression in the primary tumor
had lower EGFR scores in the corresponding lymph node
metastases. Moreover, in another two patients, EGFR
overexpression was gained in lymph node metastases
while the primary tumors had low scores. Actually, immu-
nohistochemistry is not a strickly quantitative method.
Methodological differences, e.g. in fixation procedures,
retrieval methods, and antibodies, are likely to affect the
sensitivity of EGFR staining. In addition, the criteria for
defining positive EGFR expression could also account for
part of the discrepancies between the primaries and
metastases. For example, if membrane staining in more
than 10% of the tumor cells was defined as positive EGFR
expression, regardless of pattern of cellular membrane
staining (complete or incomplete), only 3 changes could
be observed: two cases from positive to negative when the
primary lesions were compared to the corresponding
lymph node metastases, and one case changed the other
way around. Nevertheless, it seems that, in a majority of
the studied cases, EGFR expression retained in the metas-
tases.
To our knowledge, the question of EGFR status in lymph
node metastases versus primary cervical cancer has not
been addressed. From our results, it seems that EGFR
expression is stable when comparing the lymph node
metastases with the primary cervical cancers, which is sur-
prising in the light of the genomic instability that charac-
terizes most malignant tumors. Although the current
report is limited by the small sample size, our observa-
tions suggest that EGFR expression in the primary tumors,
which can readily be determined after surgery or biopsy,
might predict EGFR-positive metastases with a reasonably
high probability.
Table 2: EGFR-scores for the analyzed primary cervical 
squamous cell carcinoma and the corresponding lymph node 
metastases (n = 53)
Primary tumor EGFR-scores Lymph node metastases EGFR-scores
01 +2 +3 +
05 1 0 0
1+ 1 10 2 0
2+ 0 3 13 3
3+ 1 0 4 10
The scoring was based on a scale where 0 corresponded to 
completely negative staining, 1+ corresponded to faint perceptible 
staining of the tumor cell membranes, 2+ corresponded to moderate 
staining of the entire tumor cell membranes and 3+ was strong 
circumferential staining of the entire tumor cell membranes creating a 
fishnet pattern
Example of immunohistochemical HER2 staining of primary  cervical carcinoma, scored 0 (stained cells were less than  10% of total tumor cells) Figure 2
Example of immunohistochemical HER2 staining of 
primary cervical carcinoma, scored 0 (stained cells 
were less than 10% of total tumor cells). This case also 
had negative HER2 staining in lymph node metastasis. The 
micrograph was taken with objective × 10.BMC Cancer 2008, 8:232 http://www.biomedcentral.com/1471-2407/8/232
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In EGFR targeted radionuclide therapy, possible side
effects to normal tissues should be taken into considera-
tion, as EGFR is commonly expressed in normal cells. It
might be possible to minimize the toxicity and improve
therapeutic efficiency by using suitable targeting agents
with low uptake in critical normal tissues, and suitable
biodistribution. EGFR targeted radiotherapy might also
be possible if a tumor and its metastases have a strong
EGFR expression to ensure higher tumor uptake than in
most normal tissues or local delivery of the targeting agent
can be made.
There are conflicting results regarding the frequency of
HER2 expression in cervical cancer. High positive rate of
HER2 expression in cervical cancer has been reported in
the earlier studies [28-30]. For example, Lee et al [28]
found HER2 expression in 29.7% of the analyzed cases.
Nevin et al [29] and Niibe et al [30] reported HER2 expres-
sion in about 40% of the studied cases. However, accord-
ing to the recent reports by Chavez-Blanco et al [31] and
Kim et al [32], HER2 expression was observed in only
3.2% (1/31) and 0% (0/227), respectively, of the studied
squamous cell cervical cancer cases. The original aim of
the present study was to compare HER2 expression
between the primary uterine cervical tumors and the cor-
responding lymph node metastases. Surprisingly, none of
the cases expressed HER2 protein, neither in the primary
lesions nor in the metastases. The use of positive controls
during immunohistochemical procedures rules out the
hypothesis of false-negative reactions. The application of
HercepTest scoring criterion, the official FDA scoring
guidelines for predictive assessment in breast cancer,
might be an important reason for the low positive rate of
HER2 expression. Using the standardized HercepTest
scoring criterion, HER2 expression is considered a rare
event in cervical cancer [31,32]. Our data are consistent
with these findings. Therefore, HER2 appears to be of
poor interest as a potential target in the treatment of cer-
vical cancer.
Conclusion
The present study is the first to compare the EGFR and
HER2 receptor status in primary cervical cancers with their
lymph node metastases. For a receptor to be of interest for
targeting nuclides therapy, similar expression in both the
primary tumors and the disseminated lesions are
required. The EGFR expression seems to be common and
stable during cervical cancer metastasis, which is encour-
aging for testing of EGFR targeted radiotherapy. HER2
appears to be of poor interest as a potential target in the
treatment of cervical cancer.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
LS participated in the design of the study, carried out the
clinical and immunohistochemical data analysis; YS and
LS interpreted the histological and immunohistochemical
data; XW, ZY and DX contribute with the clinical data; and
QW conceived the study, interpreted the immunohisto-
chemical data and wrote the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
The authors thank Min Lin for help with the immunohistochemical stainings 
and Xingguo Lu for help with the photos in Figure 1 and 2. The authors 
acknowledge economical support from a grant from National Natural Sci-
ence Foundation of China to Q Wei (No. 30470501).
References
1. Par kin D M, Bray F, Ferlay J, Pisani P: Global cancer statistics,
2002.  CA Cancer J Clin 2005, 55:74-108.
2. Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS,
Sorosky J, Miller DS, Eaton LA, Fiorica JV, Gynecologic Oncology
Group Study: Randomized phase III trial of cisplatin with or
without topotecan in carcinoma of the uterine cervix: a
Gynecologic Oncology Group Study.  J Clin Oncol 2005,
23:4626-4633.
3. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood
M, Williams CJ: Survival and recurrence after concomitant
chemotherapy and radiotherapy for cancer of the uterine
cervix: a systematic review and meta-analysis.  Lancet 2001,
358:781-786.
4. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rot-
man M, Gershenson DM, Mutch DG: Pelvic radiation with con-
current chemotherapy compared with pelvic and para-
aortic radiation for high-risk cervical cancer.  N Engl J Med
1999, 340:1137-1143.
5. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA,
Clarke-Pearson DL, Insalaco S: Concurrent cisplatin-based radi-
otherapy and chemotherapy for locally advanced cervical
cancer.  N Engl J Med 1999, 340:1144-1153.
6. Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J,
Rotman M, Gershenson D, Mutch DG: Pelvic irradiation with
concurrent chemotherapy versus pelvic and para-aortic irra-
diation for high-risk cervical cancer: an update of radiation
therapy oncology group trial (RTOG) 90-01.  J Clin Oncol 2004,
22:872-880.
7. Classe JM, Rauch P, Rodier JF, Morice P, Stoeckle E, Lasry S, Houve-
naeghel G, Groupe des Chirurgiens de Centre de Lutte Contre le
Cancer:  Surgery after concurrent chemoradiotherapy and
brachytherapy for the treatment of advanced cervical can-
cer: morbidity and outcome: results of a multicenter study
of the GCCLCC (Groupe des Chirurgiens de Centre de
Lutte Contre le Cancer).  Gynecol Oncol 2006, 102:523-529.
8. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs
CL 3rd, Walker JL, Gersell D: Cisplatin, radiation, and adjuvant
hysterectomy compared with radiation and adjuvant hyster-
ectomy for bulky stage IB cervical carcinoma.  N Engl J Med
1999, 340:1154-1161.
9. Hirte HW, Strychowsky JE, Oliver T, Fung-Kee-Fung M, Elit L, Oza
AM: Chemotherapy for recurrent, metastatic, or persistent
cervical cancer: a systematic review.  Int J Gynecol Cancer 2007,
17:1194-1204.
10. Lenhard RE Jr, Osteen RT, Gansler T, eds: Clinical Oncology Atlanta,
GA: American Cancer Society, Inc; 2001. 
11. Duenas-Gonzalez A, Cetina L, Mariscal I, de la Garza J: Modern
management of locally advanced cervical carcinoma.  Cancer
Treat Rev 2003, 29:389-399.
12. Carlsson J, Forssell Aronsson E, Hietala SO, Stigbrand T, Tennvall J:
Tumour therapy with radionuclides: assessment of progress
and problems.  Radiother Oncol 2003, 66:107-117.
13. Goldberg RM: Cetuximab.  Nat Rev Drug Discov Suppl 2005:S10-11.
14. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido
S, Bianco AR, Tortora G: Antitumor effect and potentiation ofPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2008, 8:232 http://www.biomedcentral.com/1471-2407/8/232
Page 7 of 7
(page number not for citation purposes)
cytotoxic drugs activity in human cancer cells by ZD-1839
(Iressa), an epidermal growth factor receptor-selective tyro-
sine kinase inhibitor.  Clin Cancer Res 2000, 6:2053-2063.
15. Hightower M: Erlotinib (OSI-774, Tarceva), a selective epider-
mal growth factor receptor tyrosine kinase inhibitor, in com-
bination with chemotherapy for advanced non-small-cell
lung cancer.  Clin Lung Cancer 2003, 4:336-338.
16. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones
CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian
H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuxi-
mab for squamous-cell carcinoma of the head and neck.  N
Engl J Med 2006, 354:567-578.
17. Souglakos J, Kalykaki A, Vamvakas L, Androulakis N, Kalbakis K, Age-
laki S, Vardakis N, Tzardi M, Kotsakis AP, Gioulbasanis J, Tsetis D,
Sfakiotaki G, Chatzidaki D, Mavroudis D, Georgoulias V: Phase II
trial of capecitabine and oxaliplatin (CAPOX) plus cetuxi-
mab in patients with metastatic colorectal cancer who pro-
gressed after oxaliplatin-based chemotherapy.  Ann Oncol
2007, 18:305-310.
18. Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Janne PA,
Bonomi P: Phase II trial of cetuximab in patients with previ-
ously treated non-small-cell lung cancer.  J Clin Oncol 2006,
24:5253-5258.
19. Barnes DM, Miles DW: Response of metastatic breast cancer to
trastuzumab?  Lancet 2000, 355:160-161.
20. Goncalves A, Fabbro M, Lhommé C, Gladieff L, Extra JM, Floquet A,
Chaigneau L, Carrasco AT, Viens P: A phase II trial to evaluate
gefitinib as second- or third-line treatment in patients with
recurring locoregionally advanced or metastatic cervical
cancer.  Gynecol Oncol 2008, 108:42-46.
21. Cho NH, Kim YB, Park TK, Kim GE, Park K, Song KJ: P63 and EGFR
as prognostic predictors in stage IIB radiation-treated cervi-
cal squamous cell carcinoma.  Gynecol Oncol 2003, 91:346-353.
22. Kristensen GB, Holm R, Abeler VM, Trope CG: Evaluation of the
prognostic significance of cathepsin D, epidermal growth
factor receptor, and c-erbB-2 in early cervical squamous cell
carcinoma.  Cancer 1996, 78:433-440.
23. Kersemaekers AM, Fleuren GJ, Kenter GG, Broek LJ Van den, Uljee
SM, Hermans J, Vijver MJ Van de: Oncogene alterations in carci-
nomas of the uterine cervix: overexpression of the epider-
mal growth factor receptor is associated with poor
prognosis.  Clin Cancer Res 1999, 5:577-586.
24. Hale RJ, Buckley CH, Gullick WJ, Fox H, Williams J, Wilcox FL: Prog-
nostic value of epidermal growth factor receptor expression
in cervical carcinoma.  J Clin Pathol 1993, 46:149-153.
25. Kim GE, Kim YB, Cho NH, Chung HC, Pyo HR, Lee JD, Park TK,
Koom WS, Chun M, Suh CO: Synchronous coexpression of epi-
dermal growth factor receptor and cyclooxygenase-2 in car-
cinomas of the uterine cervix: a potential predictor of poor
survival.  Clin Cancer Res 2004, 10:1366-1374.
26. Lee CM, Lee RJ, Hammond E, Tsodikov A, Dodson M, Zempolich K,
Gaffney DK: Expression of HER2neu (c-erbB-2) and epidermal
growth factor receptor in cervical cancer: prognostic corre-
lation with clinical characteristics, and comparison of man-
ual and automated imaging analysis.  Gynecol Oncol 2004,
93:209-214.
27. Gaffney DK, Haslam D, Tsodikov A, Hammond E, Seaman J, Holden
J, Lee RJ, Zempolich K, Dodson M: Epidermal growth factor
receptor (EGFR) and vascular endothelial growth factor
(VEGF) negatively affect overall survival in carcinoma of the
cervix treated with radiotherapy.  Int J Radiat Oncol Biol Phys
2003, 56:922-928.
28. Lee JS, Kim HS, Jung JJ, Lee MC, Park CS: Expression of vascular
endothelial growth factor in adenocarcinomas of the uterine
cervix and its relation to angiogenesis and p53 and c-erbB-2
protein expression.  Gynecol Oncol 2002, 85:469-475.
29. Nevin J, Laing D, Kaye P, McCulloch T, Barnard R, Silcocks P, Blackett
T ,  P a t e r s o n  M ,  S h a r p  F ,  C r u s e  P :  The significance of Erb-b2
immunostaining in cervical cancer.  Gynecol Oncol 1999,
73:354-358.
30. Niibe Y, Nakano T, Ohno T, Suzuki Y, Oka K, Tsujii H: Prognostic
significance of c-erbB-2/HER2 expression in advanced uter-
ine cervical carcinoma with para-aortic lymph node metas-
tasis treated with radiation therapy.  Int J Gynecol Cancer 2003,
13:849-855.
31. Chavez-Blanco A, Perez-Sanchez V, Gonzalez-Fierro A, Vela-Chavez
T, Candelaria M, Cetina L, Vidal S, Duenas-Gonzalez A: HER2
expression in cervical cancer as a potential therapeutic tar-
get.  BMC Cancer 2004, 4:59.
32. Kim JY, Lim SJ, Park K, Lee CM, Kim J: Cyclooxygenase-2 and c-
erbB-2 expression in uterine cervical neoplasm assessed
using tissue microarrays.  Gynecol Oncol 2005, 97:337-341.
33. Wei Q, Sheng L, Shui Y, Hu Q, Nordgren H, Carlsson J: EGFR,
HER2, and HER3 expression in laryngeal primary tumors
and corresponding metastases.  Ann Surg Oncol 2008,
15:1193-1201.
34. Shang J, Shui Y, Sheng L, Wang K, Hu Q, Wei Q: Epidermal growth
factor receptor and human epidermal growth factor recep-
tor 2 expression in parotid mucoepidermoid carcinoma: pos-
sible implications for targeted therapy.  Oncol Rep 2008,
19:435-440.
35. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-
Llorca F, Rüschoff J, Tomasic G, Vijver M van de: Current perspec-
tives on HER2 testing: a review of National Testing Guide-
lines.  Mod Pathol 2003, 16:173-182.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/8/232/pre
pub